Choosing the route of drug administration for hormone therapy of the menopausal period - When is it worth to truck tablets for patches?;Wybór drogi podania w terapii hormonalnej okresu menopauzy - Kiedy warto zamienić tabletki na plastry?

Przeglad Menopauzalny

Volumn 5, Issue 5, 2006, Pages 323-328

  Pertyński, Tomasz ^a   Stachowiak, Grzegorz ^a  

^a POLISH MOTHER S MEMORIAL HOSPITAL RESEARCH INSTITUTE   (Poland)

Author keywords

Hormone therapy; Patches; Pregnancy menopause

Indexed keywords

CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; ESTRADIOL; ESTROGEN; GESTAGEN;

ARTICLE; DRUG DOSAGE FORM COMPARISON; ESTRADIOL BLOOD LEVEL; ESTROGEN THERAPY; FEMALE; HUMAN; HYPERTRIGLYCERIDEMIA; INDIVIDUALIZATION; MENOPAUSAL SYNDROME; PATIENT COMPLIANCE; PORTAL VEIN BLOOD FLOW; TABLET FORMULATION; TRANSDERMAL PATCH; TREATMENT PLANNING;

EID: 33845496769     PISSN: 16438876     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Wysowski DK, Golden L, Burke L Use of menopausal estrogens and medroxyprogesterone in Unites States. Obstet Gynecol 1995; 85: 6-10.
2. Corson SL A decade of experience with transdermal estrogen replacement therapy: overview of key pharmacologic and clinical findings. Int J Fertil 1993; 38: 79-91.
3. Boyd RA, Zegarac EA, Eldon MA, et al. Pharmacokinetic characterization of 7-day 17β-estradiol transdermal delivery system in healthy postmenopausal women. Pharm Res 1993; 10: S332.
4. Pertyński T, Stachowiak G. Przezskórne podawanie 17β-estradiolu. Postep w hormonalnej terapii zastepczej? Prze Menopauz 2004; 3: 41-8.
5. Stokes J 3rd, Kannel WB, Wolf PA, et al. Blood pressure as a risk factor for cardiovascular disease. The Framingham Study-30 years of follow-up. Hypertension 1989; 13 (5 suppl): 13-18.
6. Nickenig G, Stablein A, Wassmann S, et al. Acute effects of ACE inhibition on coronary endothelial function. J Renin Angiotensin Aldosterone Syst 2000; 1: 361-4.
7. Nicholls MG, Robertson JL. The renin-angiotensin system in the year 2000. J Hum Hypertens 2000; 14: 649-66.
8. Modena MG, Molinari R, Muia N Jr, et al. Double-blind randomized placebo controlled study of transdermal estrogen replacement therapy on hypertensive postmenopausal women. Am J Hypertens 1999; 12: 1000-8.
9. Mueck AO, Seeger H. Effect of hormone therapy on BP in normotensive and hypertensive postmenopausal women. Maturitas 2004; 49: 189-203.
10. Stevenson JC, Oladipo A, Manassiev N, et al. Randomized trial of effect of transdermal continuous combined hormone replacement therapy on cardiovascular risk markers. Br J Haematol 2004; 124: 802-8.
11. Lowe GD, Upton MN, Rumley A, et al. Different effects of oral and transdermal hormone replacement therapies on factor IX, APC resistance, t-PA, PAI and C-reactive protein - a cross-sectional population survey. Thromb Haemost 2001; 86: 550-6.
12. Sumino H, Ichikawa S, Ohyama Y, et al. Effect of transdermal hormone replacement therapy on the monocyte chemoattractant protein-1 concentrations and other vascular markers and on endothelial function in postmenopausal women. Am J Cardiol 2005; 96: 148-53.
13. Menon DV, Vongpatanasin W. Effects of transdermal estrogen replacement therapy on cardiovascular risk factors. Treat Endocrinol 2006; 5: 37-51.
14. Persico N, Mancini F, Artini PG, et al. Transdermal HRT and Doppler findings in normotensive and hypertensive postmenopausal patients. Ultrasound Obstet Gynecol 2005; 26: 651-7.
15. Kurtay G, omen B, Erguder I. A comparison of effects of sequential transdermal administration versus oral administration of estradiol plus noretisterone acetate on serum NO levels in postmenopausal women. Maturitas 2006; 53: 32-8.
16. Nicoloaides AN. Zakrzepica żył głebokich. Chirurgia Współczesna 1993; 1: 151-2.
17. Vehkavaara S, Silveira A, Hakala-Ala-Pietila T, et al. Effects of oral and transdermal estrogen replacement therapy on markers of coagulation, fibrinolysis, inflammation and serum lipids and lipoproteins in postmenopausal women. Thromb Haemost 2001; 85: 619-25.
18. Lowe GD, Upton MN, Rumley A, et al. Different effects of oral and transdermal hormone replacement therapies on factor IX, APC resistance, t - PA, PAI and C-reactive protein - a cross-sectional population survey. Thromb Haemost 2001; 86: 550-6.
19. Martinez C, Basurto L, Zarate A, et al. Transdermal estradiol does not impair hemostatic biomarkers in postmenopausal women. Maturitas 2005; 50: 39-43.
20. Canonico M, Plu-Bureau G, Scarabin PY. Hormone therapy and venous thromboembolism among postmenopausal women: impact of progestogens. The ESTHER study. Climacteric 2005; 8 (supl. 2): 125.
21. Straczek C, Oger E, Yon de Jonage-Canonico MB, et al. Estrogen and Thromboembolism Risk (ESTHER) Study Group. Prothrombotic mutations, hormone therapy, and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration. Circulation 2005; 112: 3495-500.
22. Herkert O, Kuhl H, Sandow J, et al. Sex steroids used in hormonal treatment increase vascular procoagulant activity by inducing thrombin receptor (PAR-1) expression: role of the glucocorticoid receptor. Circulation 2001; 104: 2826-31.
23. Anderson B, et al. Estrogen replacement therapy decreases hyperandrogenicity and improves glucose homeostasis and plasma lipids in postmenopausal women with noninsulin-dependent diabetes mefitus. J Clin Endocrinol Metab 1997; 82: 638-43.
24. Rossi R, Origliani G, Modena MG. Transdermal 17-beta-estradiol and risk of developing type 2 diabetes in population of healthy, nonobese postmenopausal women. Diabetes Care 2004; 27: 645-9.
25. Kanaya AM, Herrington D, Vittinghoff E, et al. Glycemic effects of postmenopausal hormone therapy: the Heart and Estrogen/progestin Replacement Study. A randomized, double-blind, placebo controlled trial. Ann Intern Med 2003; 138: 1-9.
26. Margolis KL, Bonds DE, Rodabough RJ, et al. Effect of oestrogen plus progestin on the incidence of diabetes in postmenopausal women: results from the Women's Health Initiative Hormone Trial. Diabetologia 2004; 47: 1175-87.
27. O'Sullivan AJ, Ho KK. A comparison of the effects of oral and transdermal estrogen replacement on insulin sensitivity in postmenopausal women. J Clin Endocrinol Metab 1995; 80: 1783-8.
28. Godsland IF, Gangar K, Walton C, et al. Insulin resistance, secretion, and elimination in postmenopausal women receiving oral or transdermal hormone replacement therapy. Metabolism 1993; 42: 846-53.
29. Dembińska-Kieć A. Gospodarka lipidowa po menopauzie. Pol Arch Med Wewn 1998; 100: 211-9.
30. Kornacewicz-Jach Z. Choroby serca i naczyń w wieku menopauzalnym. W: Diagnostyka i terapia wieku menopauzalnego. Pertyński T (red.). Urban & Partner, Wrocław 2004; 23-39.
31. Chen FP, Lee N, Soong YK, et al. Comparison of transdermal and oral estrogen-progestin replacement therapy: effects on cardiovascular risk factors in postmenopausal women. Menopause 2001; 8: 347-52.
32. Sanada M, Tsuda M, Kodama I, et al. Substitution of transdermal estradiol during oral estrogen-progestin therapy in postmenopausal women: effects on hypertriglyceridemia. Menopause 2004; 11: 331-6.
33. Van Erpecum KJ, Van Berge Henegouwen GP, Verschoor L, et al. Different hepatobiliary effects of oral and transdermal estradiol in postmenopausal women. Gastroenterology 1991; 100: 482-8.
34. Mueck AO. Seeger H. Smoking, estradiol metabolism and hormone replacement therapy. Curr Med Chem Cariovasc Hematol Agents 2005; 3: 45-54.
35. Fournet N, Judd H. Menopause overview. W: Reproductive Medicine and Surgery. St. Louis 1995; 961-81.
36. Cagnacci A, Malmusi S, Aragino S, et al. Influence of transdermal estradiol in the regulation of leptin levels of postmenopausal women: a double blind, placebo-controlled study. Menopause 2002; 9: 65-71.
37. Cano A. Compliance to hormone replacement therapy in menopausal women controlled in a third level academic centre. Maturitas 1994; 20: 91-9.
38. Balfour JA, Heel RC. Transdermal estradiol: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the treatment of menopausal complaints. Drugs 1990; 40: 561-82.
39. Hesch RD, Kenemans P. Hormonal prevention of breast cancer: proposal for a change in paradigm. Br J Obstet Gynaecol 1999; 106: 1006-18.
40. Kandouz M, Lombet A, Perrot JY, et al. Proapoptotic effects of antiestrogens, progestins and androgen in breast cancer cells. J Steroid Biochem Mol Biol 1999; 69: 463-71.
41. Writing group for the women's health initiative investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the women's health initiative randomized controlled trial. JAMA 2002; 288: 321-33.
42. Beral V and Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003; 362: 419-27.
43. Warner E, Lockwood G, Trichler D, et al. The risk of breast cancer associated with mammographic parenchymal patterns: a meta-analysis of the published literature to examine the effect of method of classification. Cancer Detect Prev 1992; 16: 67-72.
44. Lundstrom E, Christov A, Kersemaekers W, et al. Effects of tibolone and continuous combined replacement therapy on mammographic breast density. Am J Obstet Gynecol 2002; 186: 717-22.
45. Speroff L. The meaning of mammographic breast density in users of postmenopausal hormone therapy. Maturitas 2002; 41: 171-5.
46. Topal NB, Ayhan S, Topal U, et al. Effects of hormone replacement therapy regiments on mammographic breast density: the role of progestins. J Obstet Gynaecol Res 2006; 32: 305-8.
47. Christodoulakos GE, Lambrinoudaki IV, Voutrsi AD, et al. The effect of low dose hormone therapy on mammographic breast density. Maturitas 2006; 54: 78-85.
48. Harvey J, Scheurer C, Kawakami FT, et al. Hormone replacement therapy and breast density changes. Climacteric 2005; 8: 185-92.